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Abstract 
Introduction: Incidental findings on CT attenuation correction images undertaken as part of myocardial 
perfusion scintigraphy may represent undiagnosed malignancy, but their routine review and reporting remains 
controversial.  
Methods: We present a series of 10 primary thoracic cancers incidentally detected in this way. They were 
identified as part of a retrospective review of incidental CT attenuation correction findings in 3122 consecutive 
myocardial perfusion studies over a forty-month period.  
Results: The nature and location within the thorax of the incidental findings which represented undiagnosed 
malignancy was varied. Early detection allowed curative surgical treatment to be undertaken in four cases, 
with no recurrence or metastasis at one year in these patients. The rate of new primary cancer detection was 
similar to previous studies. 
Conclusions: This series highlights the need for mandatory review and reporting with appropriate further 
investigation of incidental CT attenuation correction findings, and the potential of this to impact patient 
outcomes. The importance of clear communication between the nuclear medicine department and the 
treating medical team, to both avoid unnecessary delay in urgent cases clearly suspicious for malignancy and 
to ensure that appropriate follow-up of potentially important non-urgent findings is not missed, cannot be 
over-emphasised. 
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Text 
Introduction 
Myocardial perfusion imaging (MPI) is an investigation widely used in the clinical evaluation of ischaemic heart 
disease. The diagnostic accuracy of MPI can be improved by the addition of a low -dose computed tomography 
(CT) scan performed on an integrated scanner through a limited section of the thorax to provide attenuation 
correction of the functional single positron emission computed tomography (SPECT) images.
1, 2 
This hybrid 
imaging technique is used in many centres - though not all.  
The low-dose CT is intended for attenuation correction alone and delivers a reduced ionizing radiation dose 
compared to diagnostic CT (standard dose, contrast-enhanced CT acquired with breath-holding). It typically 
includes significant portions of the lungs, mediastinum and upper abdomen in its field of view and produces 
low resolution images of these areas which are not of diagnostic quality. The appropriate approach to 
reviewing and/or reporting on these images is controversial. The inferior resolution renders it difficult to 
characterize any incidental lesions as does the absence of intravenous contrast. The images are also limited in 
the anatomic area they cover and more susceptible to artefact compared to standard diagnostic CT.
3
 
Conversely, a considerable number of incidental findings can be identified on the CT attenuation correction 
(CTAC) images which may be of clinical significance. 
An incidental finding is one which is unexpected and unrelated to the primary indication for the investigation, 
and they are particularly commonly encountered within the thorax by CT imaging modalities.
4
 Any incidental 
finding which is of clinical concern for the potential to cause harm or which may provide benefit to the 
patient’s care is significant and generally necessitates further evaluation.
5
 Incidental findings of potential 
clinical significance have been reported in 2-33% of SPECT-CT MPI studies.
6-9
  These may or may not prove to 
actually be clinically significant after further evaluation. The majority are found not to be of clinical 
consequence – such as benign liver cysts. Pulmonary nodules are the most commonly identified lesion, seen in 
up to 26.8% of cases.
7
 Most of these nodules prove to be benign but can represent early, subclinical lung 
cancer. New primary lung cancers first detected as incidental pulmonary nodules on CTAC in MPI have been 
described in published reviews and a case report.
6-10 
Despite this, SPECT-CT incidental findings continue to 
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cause a clinical dilemma with the most recent and largest review counter-intuitively advising against their 
routine reporting.
3, 9
 
Case Series 
We present a series of 10 primary thoracic malignancies first detected as an incidental finding on CTAC images 
in MPI. These occurred over the course of a forty-month period from January 2013 to April 2016 at a single 
tertiary cardiothoracic centre, during which 3122 scans were performed. They were identified following 
retrospective audit of consecutive MPI reports produced during this time. All MPI studies which resulted in a 
formal report were initially eligible for inclusion, with cases in which the low-dose CT did not occur (e.g. due to 
patient claustrophobia) then excluded. After initial review of all MPI reports, each case where a potentially 
clinically significant incidental CTAC finding was reported was assessed further. Medical imaging and pathology 
databases and hospital medical records were interrogated to determine if relevant further investigations were 
undertaken, with the cases in which the incidental CTAC finding proved to represent undiagnosed malignancy 
identified. All MPI reports were issued by senior consultant/attending nuclear medicine physicians, accredited 
by the Royal Australasian College of Physicians (RACP) and Australasian Association of Nuclear Medicine 
Specialists (AANMS), who had completed the cross-sectional anatomy education for physicians operated by 
the AANMS and are regarded as sufficiently skilled to interpret low-dose/limited-field/non-contrast CT images. 
The images were reviewed in multiple window settings (soft tissue, lung and bone). The project was declared 
exempt from full ethical review as an audit/quality assurance study by The Prince Charles Hospital Human 
Research Ethics Committee prior to commencement. 
Gated myocardial perfusion images were acquired between 5 and 60 minutes following the peripheral 
intravenous administration of technetium-labelled sestamibi radiopharmaceutical (Cardiolite®, Lantheus 
Medical Imaging®, North Billerica, MA) reconstituted according to the manufacturer’s product inset 
instructions.
11
 The dose was determined based on the patient’s weight as recommended by the guidelines 
issued by the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the European Association of 
Nuclear Medicine (EANM).
12, 13
 Images were acquired with a Symbia T6 SPECT-CT system (Siemens Healthcare 
Diagnostics, Tarrytown, NY) which combines a dual-head gamma camera with a 6-slice CT scanner. All scans 
were acquired with a general-purpose collimator and 64x64 matrix. The total number of projections was 128 
(64 stops for each of the two gamma camera heads) and each stop was 20 seconds. Subsequent to SPECT 
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acquisition, a low-dose CT was acquired (120kV, 20mAs/slice, 16x1.5 collimator, 0.5s rotation time, pitch of 
0.813).   
As are summarised in Table 1, there were five male and five female patients with a mean [range] age of 73 [63-
78] years at time of MPI. The indication for MPI was investigation of chest pain or dyspnoea in nine cases with 
one performed as part of pre-operative assessment prior to abdominal aortic aneurysm repair. The most 
recent thoracic imaging for each patient prior to MPI had revealed a potential lesion in the region of the 
incidental MPI finding in only two cases. In both an ill-defined opacity had been seen on chest x-ray. In five 
other cases a chest x-ray had been performed in the preceding year with no abnormality reported in the 
region of interest, and in one instance a CT chest had been done 16 months previously. No previous thoracic 
imaging had been performed in the remaining two cases. The anatomic distribution of the incidental findings 
was broad, including the upper and lower lung zones bilaterally as described in Table 1. All of the incidental 
lung lesions were detected based on the CTAC findings, none of them bore focal radiotracer uptake as an 
additional “hint” of their presence. 
The incidental finding was described in the MPI report as a pulmonary mass, nodule or opacity in eight of the 
ten cases, with the size of the lesion ranging from 8-65 millimetres (mm). Of these eight cases, a similar sized 
lesion (at the corresponding anatomic site) suspicious for malignancy was seen on follow-up diagnostic CT in 
four patients, and the lesion had increased in size in the other four patients. A biopsy was prompted in all eight 
of these cases based on appearance on diagnostic CT. 
The remaining two incidental findings comprised an area of lung consolidation and a suspicious pleural 
effusion associated with pleural thickening. The pleural effusion failed to resolve despite multiple drainage 
procedures and biopsy was performed when further focal increase in pleural thickening was seen on follow-up 
CT. Follow-up of the consolidative lesion with higher resolution CT revealed a nodular focus of consolidation 
with distal atelectasis, which was then biopsied. This case is illustrated as an example with Figures 1-3 showing 
the appearance of the malignancy on CTAC in MPI, diagnostic CT and positron emission tomography. While the 
significance of the initial consolidation on CTAC was not fully clear, appearance on follow-up was immediately 
concerning for malignancy. This highlights the importance of diagnostic imaging for all 
suspicious/indeterminate lesions seen on low-dose scans to allow proper characterisation, and that discrete 
nodules alone are not the only potentially important incidental finding.  
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Urgent further investigation was directly advised in the MPI report in seven cases and six-month serial 
evaluation in one case, with no specific recommendation made in the remaining two cases (with the findings 
of consolidation and effusion). The median [range] time from MPI to further investigation was 39.5 [7-221] 
days and in all cases, this was in the form of further imaging with CT. Median [range] time to attempted tissue 
biopsy for histologic assessment was 111 [13-325] days. This provided a tissue diagnosis in all but one case, 
where formal histology was only determined after surgical resection at 203 days post-MPI. 
Histologically, there were six cases of lung adenocarcinoma, two cases squamous cell carcinoma and one case 
each of small cell lung cancer and malignant mesothelioma. Four cancers were detected at a sufficiently early 
stage to allow curative surgical resection to be undertaken, and all four had no evidence of recurrence or 
metastasis with at least one year of follow-up. 
Diagnostic CT was recommended in 115 of the total 3122 MPI cases for further investigation of an incidental 
pulmonary lesion (3.7% of cases). None of the patient cohort outside of the 10 cancer cases underwent a 
subsequent biopsy or had a thoracic malignancy diagnosed at our facility during the studied period. This may, 
however, have occurred at other facilities without our knowledge. Details of further imaging studies or 
procedures performed – and any pathology results – in private facilities would not be available. Our radiology 
and pathology information systems only have access to data from public/government hospitals. It is also 
possible that lung cancers beyond the CTAC field were diagnosed elsewhere, or that lung cancers will be 
diagnosed in this cohort in the future – within or outside the CTAC field.  
Discussion 
Lung cancer is the leading cause of cancer death worldwide.
14
 As lung cancers and ischaemic heart disease 
share common risk factors, in particular cigarette smoking, patients undergoing MPI already represent a high-
risk group. Lung cancer is often asymptomatic in the early stages and can be diagnosed incidentally as a result 
of unrelated investigations.
15
 As the prognosis of lung cancer is closely related to disease stage, earlier 
detection can greatly enhance the treatment options and prognosis and may allow for curative surgical 
resection. Four of the ten patients in this series were suitable for curative surgery because of incidental 
detection of early stage malignancy, and there was no evidence of recurrent or metastatic disease at one-year 
follow-up in these four cases. Furthermore, the potential morbidity associated with chemotherapy and 
radiotherapy had the cancer been diagnosed at a later stage was avoided. 
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There were 10 cases of new primary thoracic malignancy identified in 3122 MPI cases. This equates to a 
detection rate of 0.32%. Rates of primary thoracic cancer detection as an incidental CTAC finding in previous 
studies are similar, ranging from 0.12% to 0.52%.
6-9
 Thus our findings from our series are consistent with 
previously published studies. However, the number of malignancies missed on CTAC in this cohort is not 
known and we have not included non-malignant or metastatic lesions. 
Low-dose CT has emerged as an effective screening tool for lung cancer in recent years. It has been shown to 
reduce mortality in high-risk groups with a significant exposure to cigarette smoking.
16-18
 MPI with CTAC 
provides a low-dose CT through a considerable portion of the lung fields in a patient population at higher risk 
for lung cancer development, and as shown here can identify early cancers. While the rates of cancer 
detection on CTAC cannot be directly compared to low-dose CT screening programs, it does highlight the 
potential to reduce mortality through early lung cancer detection.  
The incidental CTAC findings that proved to represent malignancy were heterogeneous in nature and anatomic 
location. Chest radiograph was unhelpful (or not performed) in all but two cases. There was wide variation in 
the size of pulmonary nodular/mass lesions, although most had a sufficiently suspicious appearance at time of 
MPI for urgent further evaluation to be advised. This suggests that while caution may be advised generally in 
the reporting of all incidental findings, review of the CTAC images should be mandatory. The recently updated 
guidelines on the appropriate management of pulmonary nodules detected incidentally are based on nodule 
size, with a diameter of eight millimetres the threshold for the highest risk group.
19
 The use of such guidelines 
on low-resolution CTAC images is supported by this series, with each nodule measuring at least eight 
millimetres, and by a previous study which described three lung cancers incidentally detected as nodules of 
greater than ten millimetres on CTAC in MPI.
7 
The malignancies were distributed throughout the thorax and 
although CTAC images cover only a limited section of the chest, this demonstrates the importance of routine 
review of all areas as no one anatomic zone is likely to be of greater importance. The position of reporting such 
incidental findings would be strengthened if reinforced overtly by the MPI guidelines of major nuclear 
medicine bodies such as SNMMI and EANM.
12, 13 
The CTAC images produced in MPI are routinely reviewed and reported at our institution. Significant incidental 
findings are discussed directly with the treating team at the time of report. The overall median time to further 
investigation was 39.5 days and was 36 days in the seven cases where urgent follow-up was advised in MPI 
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report. The median time to tissue biopsy of 111 days was surprisingly long and may suggest that these cases 
should have been managed more urgently by the referring team. The factors involved in any delay in 
investigation and the impact on clinical outcome were not reviewed any further but are a topic for future 
study. The importance of clear communication between the nuclear medicine department and the treating 
medical team is obvious to avoid unnecessary delay in urgent cases and to ensure follow-up of potentially 
important non-urgent findings is not missed. 
Discussion regarding the cost-effectiveness of routinely reporting and further investigating incidental CTAC 
findings is ongoing.
3, 9
 While the work-up of pulmonary nodules can be resource intensive and the detection 
rate of cancer is relatively low, the treatment of advanced malignancy carries a large economic and social 
burden. The complexities of the exact calculations are beyond the scope of this article. 
Conclusions 
In summary, in the context of ongoing debate regarding the appropriate overall approach to management of 
incidental findings in MPI, this case series highlights the potential for clinically significant malignant disease to 
be identified. It illustrates the importance of at least mandatory review of CTAC images as incidental lesions 
are often clearly concerning for malignancy, and the need for routine reporting and appropriate follow-up of 
suspicious incidental findings due to their potential to represent undiagnosed malignancy. Further research is 
needed to produce consensus guidelines on the most appropriate approach to reporting and investigating 
incidental CTAC findings during MPI. 
Clinical Practice Points 
Low-dose, non-breathing holding CT images of a significant portion of the thorax can be used to provide CT 
attenuation correction (CTAC) in myocardial perfusion scintigraphy enhancing the accuracy of evaluation for 
myocardial ischaemia. Incidental findings of potential clinical significance, most commonly pulmonary nodules, 
are seen on the CTA  images in a considerable number of cases and may represent undiagnosed malignancy. 
The routine review and/or reporting of these incidental findings is controversial however, and recent studies 
have advised against it. We present a series of 10 primary thoracic malignancies incidentally detected on CTAC 
images in MPI identified following retrospective review of 3122 consecutive MPI studies. Early detection 
allowed curative surgical treatment to be undertaken in four cases, with no recurrence or metastasis at one 
year in these patients. The nature and location within the thorax of the incidental low-dose CT findings which 
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represented undiagnosed malignancy was varied. Review of CTAC images in MPI for incidental lesions and 
reporting of any suspicious findings should be mandatory given the ability to detect undiagnosed malignancy 
and potentially improve patient outcomes. Direct communication of suspicious incidental findings between 
the nuclear medicine physicians and referring doctors at time of reporting may help to reduce the interval 
between MPI and definitive diagnosis. The position would be further strengthened if reinforced in the 
guidelines of the major nuclear medicine associations. 
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Figures 
 
 
FIGURE 1. Axial low-dose CT demonstrating an incidental lung cancer detected on CT attenuation correction 
during MPI (case 10). An area of consolidation within the right upper lobe is seen. 
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FIGURE 2. Axial diagnostic CT of the lesion in Figure 1 (undertaken 70 days later). It shows a 20mm area of 
nodular consolidation with distal consolidation/atelectasis.
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Figure 3. On fluorodeoxyglucose positron emission tomography (with combined low-dose CT), radiotracer was 
avidly taken up by the tumour demonstrated in Figures 1 and 2 as well as in ipsilateral hilar, subcarinal and 
precarinal lymph nodes. Subsequent biopsy revealed adenocarcinoma. 
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Table 1. Key characteristics of each case 
Case Indication 
for MPI 
Age at 
MPI 
(Sex) 
Most recent 
thoracic imaging 
prior to MPI 
(and findings) 
Nature of 
incidental 
finding in MPI 
report 
Time to 
further 
investigation 
(days) 
Time to 
biopsy 
(days) 
Diagnosis Stage at 
diagnosis 
(TNM) 
Initial 
treatment 
 
1 
 
Chest pain 
 
78 
(Female) 
 
Chest x-ray 11 
days prior: ill-
defined right mid-
zone consolidation 
 
 
Irregular mass in 
right mid-zone 
 
21 
 
36 
 
Adenocarcinoma 
 
T2a N0 M0 
 
Radiotherapy 
2 Chest pain 72 
(Female) 
CT chest 16 
months prior: nil 
significant 
49mm right lower 
lobe solid mass 
with associated 
lymphadenopathy 
16 37 Small cell lung 
cancer 
Limited 
stage small 
cell lung 
cancer 
T2b N3 M0 
Chemo-
radiation 
 
3 Chest pain 74 
(Female) 
Chest x-ray on 
same day: nil 
significant 
65mm left hilar 
mass with multiple 
associated lung 
nodules 
7 13 Adenocarcinoma T3 N2 M1b Chemo-
radiation 
4 Chest pain 
 
73 
(Female) 
Chest x-ray 2 days 
prior: nil 
significant 
16mm irregular, 
non-calcified left 
lower lobe nodule 
36 84 Adenocarcinoma T1a N0 M0 Surgery 
5 Dyspnoea 
on exertion 
63 
(Male) 
None performed 10mm right lower 
lobe nodule 
100 133 Squamous cell 
carcinoma 
T2a N0 M0 Surgery 
6 Chest pain 65 
(Male) 
Chest x-ray 1 year 
prior: calcified 
pleural plaques, 
no pleural effusion 
Right-sided pleural 
effusion 
associated with 
bilateral pleural 
plaques 
 
92 261 Malignant 
Mesothelioma 
T4 N0 M0 Chemotherapy 
7 Dyspnoea 
on exertion 
73 
(Female) 
Chest x-ray 7 
months prior: nil 
significant 
 
8mm left upper 
lobe nodule 
221 325 Adenocarcinoma T1a N0 M0 Surgery 
8 Pre-
operative 
assessment 
 
78 
(Male) 
Chest x-ray 6 
months prior: nil 
significant 
Two left lower 
lobe nodules, 
largest 27mm 
37 54 Squamous cell 
carcinoma 
T2a N1 
M1b 
Chemo-
radiation 
9 Chest pain 78 
(Male) 
Chest x-ray 2 days 
prior: small left 
mid-zone opacity 
 
20mm left upper 
lobe opacity 
42 50 Adenocarcinoma T1b N0 M0 Surgery 
10 Chest pain 
and 
dyspnoea 
on exertion 
76 
(Male) 
None performed Right upper lobe 
consolidation 
70 120 Adenocarcinoma T2a N3 M0 Chemo-
radiation 
 
          
 
Table abbreviations 
-MPI: myocardial perfusion imaging 
-TNM: lung cancer TNM (tumour, nodes, metastasis) classification and staging system 
-CT: computed tomography 
-mm: millimetres
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